ROR1, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-ROR1, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | ROR1, Human |
| Clone | REA1051 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | Vio Bright V423 conjugate |
| Size | 100 tests in 200 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | ROR1 Antibody, anti-human, Vio® Bright V423, REAfinity™. Clone REA1051 recognizes the human ROR1 antigen, also known as receptor tyrosine kinase-like orphan receptor 1. ROR1 has characteristics of an oncofetal gene and was recently identified to be overexpressed at the gene and protein levels in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). ROR1 expression has also been detected in ovarian cancer, renal cancer, melanoma, and lung adenocarcinoma, suggesting a general role of ROR1 in cancer genesis and/or maintenance. Moreover, ROR1 expression has been found in undifferentiated embryonic stem cells, in adipose tissue, at early stages of B cell development, but not in major adult tissues. Therefore, ROR1 is a potential therapeutic target and a biomarker to identify and enumerate malignant cells in CLL and MCL blood samples via flow cytometry. | Additional information: Clone REA1051 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | NTRKR1 |
| Gene, Accession # | Gene ID: 4919 |
| Catalog # | 130-128-193 |
| Price | $500 |
| Order / More Info | ROR1, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Fukuda, T. et al. (2008) Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl. Acad. Sci. U.S.A. 105: 3047-3052. | Hudecek, M. et al. (2010) The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116 (22): 4532-4541. | Yang, J. et al. (2011) Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One 6 (6): e21018. | Daneshmanesh, A. H. et al. (2012) Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 26 (6): 1348-1355. | Baskar, S. et al. (2012) Targeting malignant B cells with an immnunotoxin against ROR1. mAbs 4 (3): 349-361. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies